1: Perez-Garcia G, Gama Sosa MA, De Gasperi R, Tschiffely AE, McCarron RM, Hof
PR, Gandy S, Ahlers ST, Elder GA. Blast-induced "PTSD": Evidence from an animal
model. Neuropharmacology. 2019 Feb;145(Pt B):220-229. doi:
10.1016/j.neuropharm.2018.09.023. Epub 2018 Sep 15. PMID: 30227150.
2: Perez-Garcia G, De Gasperi R, Gama Sosa MA, Perez GM, Otero-Pagan A,
Tschiffely A, McCarron RM, Ahlers ST, Elder GA, Gandy S. PTSD-Related Behavioral
Traits in a Rat Model of Blast-Induced mTBI Are Reversed by the mGluR2/3
Receptor Antagonist BCI-838. eNeuro. 2018 Jan 30;5(1):ENEURO.0357-17.2018. doi:
10.1523/ENEURO.0357-17.2018. PMID: 29387781; PMCID: PMC5790754.
3: Hashimoto K, Malchow B, Falkai P, Schmitt A. Glutamate modulators as
potential therapeutic drugs in schizophrenia and affective disorders. Eur Arch
Psychiatry Clin Neurosci. 2013 Aug;263(5):367-77. doi:
10.1007/s00406-013-0399-y. Epub 2013 Mar 1. PMID: 23455590.
4: Kim SH, Steele JW, Lee SW, Clemenson GD, Carter TA, Treuner K, Gadient R,
Wedel P, Glabe C, Barlow C, Ehrlich ME, Gage FH, Gandy S. Proneurogenic Group II
mGluR antagonist improves learning and reduces anxiety in Alzheimer Aβ oligomer
mouse. Mol Psychiatry. 2014 Nov;19(11):1235-42. doi: 10.1038/mp.2014.87. Epub
2014 Aug 12. PMID: 25113378; PMCID: PMC4217144.
5: Perez-Garcia G, Bicak M, Haure-Mirande JV, Perez GM, Otero-Pagan A, Gama Sosa
MA, De Gasperi R, Sano M, Barlow C, Gage FH, Readhead B, Ehrlich ME, Gandy S,
Elder GA. BCI-838, an orally active mGluR2/3 receptor antagonist pro-drug,
rescues learning behavior deficits in the PS19 MAPTP301S mouse model
of tauopathy. Neurosci Lett. 2023 Feb 16;797:137080. doi:
10.1016/j.neulet.2023.137080. Epub 2023 Jan 16. PMID: 36657633; PMCID:
PMC9974759.